

**FOUNDATION FUNDING OPPORTUNITIES: APRIL 1, 2022**

Please contact Corporate & Foundation Relations in the Office of Development at [devcfr@mgh.harvard.edu](mailto:devcfr@mgh.harvard.edu) if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

The MGB **Proposal Deadline Policy** establishes internal deadlines for sponsored research proposals to ensure that submissions meet sponsor criteria and institutional/regulatory requirements. Deadlines are:

- The complete Administrative Components are due to Research Management (RM) on or before the **8th Business Day** by 5 PM.
- The Final (Science) Components are due to RM on or before the **3rd Business Day**.

**Have you updated your MGH Researcher profile?  
Go to <https://researchers.mgh.harvard.edu/> today!**

Table of Contents

1. [Expansion Award for Single Ventricle Research](#), Additional Ventures
2. [AACR-Genmab Non-Hodgkin B-cell Lymphoma Research Fellowship](#), American Association for Cancer Research (AACR)
3. [Pandemic Antiviral Discovery RfP on Henipavirus](#), Bill and Melinda Gates Foundation (BMGF)
4. [Cancer Research Grants](#), Elsa U. Pardee Foundation
5. [HD Human Biology Project](#), Huntington's Disease Society of America
6. [User-Centric Insulin Pumps](#), JDRF
7. [Improving Detection of Neurotoxicity in Immunotherapies](#), Johnson & Johnson (J&J)
8. [Maternal-Fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity](#), Johnson & Johnson (J&J)
9. [Fellows Award in Premature Mortality](#), MQ: Transforming Mental Health
10. [Childhood Eczema Challenge Grant](#), Pediatric Dermatology Research Alliance (PeDRA)

## **1. Expansion Award for Single Ventricle Research, Additional Ventures**

The Additional Ventures Expansion Award Program (EAP) is an annual research program that funds:

1. Expansion of existing studies within the Single Ventricle (SV) research community, and
2. The addition of SV-directed aims to ongoing studies within the cardiovascular development field.

These awards fill a gap in existing funding opportunities to promote scientific advancement of teams with a documented history of award success in and adjacent to the SV research community.

Single Ventricle Heart Disease is an understudied and underfunded area that requires a multi-disciplinary approach from a research and clinical care perspective. Additional Ventures aims to accelerate research that will lead to both improved care and treatments based on a mechanistic understanding of SV. We have developed a research roadmap in partnership with investigators across disciplines that identifies strategic solutions to address these gaps and challenges, which is intended to guide a decade's worth of research efforts and serve as a framework for coordinating global resources to advance SV research and clinical care.

Citizenship: Unrestricted

Award Amount: \$50,000 for 1 year

Indirect Costs: None

MGB Research Management Deadline: April 21, 2022

Proposal Deadline: May 2, 2022

Website: <https://www.additionalventures.org/funding/expansion-award/>

## **2. AACR-Genmab Non-Hodgkin B-cell Lymphoma Research Fellowship, American Association for Cancer Research (AACR) **NEW!****

The AACR-Genmab Non-Hodgkin B-cell Lymphoma Research Fellowship represents a joint effort to encourage and support postdoctoral or clinical research fellows to conduct non-Hodgkin B-cell lymphoma research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to non-Hodgkin B-cell lymphoma. This fellowship especially encourages applications for projects that will advance our knowledge and practice for treating non-Hodgkin B-cell lymphoma with, but not limited to, the following:

- Antibody-based therapeutics (e.g. monoclonal antibodies, antibody drug conjugates, cell engagers, etc.)
- Cell therapies
- Vaccines
- Other Immunomodulators

Eligibility requirements (partial list):

- Hold a mentored research position with the title of postdoctoral fellow, clinical research fellow, or the equivalent
  - If eligibility is based on a future position, the position must be confirmed at the time of application and CANNOT be contingent upon receiving this grant.
  - If the future position is at a different institution than the applicant's current institution, the applicant must contact AACR's Scientific Review and Grants Administration Department (AACR's SRGA) at [grants@aacr.org](mailto:grants@aacr.org) before submitting their application for information on additional verification materials/signatures that may be required.
- Have completed their most recent doctoral degree within the past five years
  - Applicants with a medical degree must have completed their most recent doctoral degree or medical residency - whichever date is later - within the past five years.

Citizenship: Unrestricted

Award Amount: \$120,000 paid over 2 years

Indirect Costs: None

MGB Research Management Deadline: May 10, 2022

Application Deadline: May 19, 2022

Website: <https://www.aacr.org/grants/aacr-genmab-non-hodgkin-b-cell-lymphoma-research-fellowship/>

### **3. Pandemic Antiviral Discovery RfP on Henipavirus, Bill and Melinda Gates Foundation (BMGF) **NEW!****

This RfP will support projects that seek to elucidate the molecular determinants of henipavirus replication, pathogenesis and transmission for the purpose of developing therapeutic discovery programs targeting virus and/or host-specific targets important for virus replication. Projects can be of both novel and exploratory nature and of later-stage validation/developmental nature.

Specific areas of interest include:

- Biomarkers of henipavirus pathogenesis in humans to facilitate drug discovery programs and clinical evaluation of antiviral therapies.
- Identification and validation of virus and/or host targets necessary for henipavirus replication that could serve as starting points for therapeutic discovery.
- Inhibitors of virus and/or host targets that are broadly active across paramyxoviruses with a preference for henipaviruses.
- Novel tools and assays for studying henipavirus replication and pathogenesis that do not require BSL-4 containment.
- Target based approaches for henipavirus antiviral discovery and development.

Projects on vaccines, antibody therapy, and epidemiology will not be considered for funding.

The PAD founding partners Bill & Melinda Gates Foundation, Open Philanthropy and Novo Nordisk Foundation will have access to all the proposals submitted to this RfP.

Eligibility requirements (partial list):

- PAD seeks to actively engage researchers from all over the world as part of the drug discovery process, but applicants must be established investigators with their own line of research and must be employed for the duration of the project at the administering institution registered in the proposal.

Citizenship: Unrestricted

Award Amount: \$10 million available for 1-3 years

Indirect Costs: Unspecified

MGB Research Management Deadline: April 26, 2022

Application Deadline: May 5, 2022

Website: <https://padinitiative.com/henipavirus-request-for-proposals-2022/>

#### **4. Cancer Research Grants, Elsa U. Pardee Foundation**

The Elsa U. Pardee Foundation funds research to investigators proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Citizenship: United States

Award Amount: By design, there are no limits set on the grant amount that can be requested. It must be reasonable and clearly supported by the scope of the project outlined in the application.

Indirect Costs: 5%

MGB Research Management Deadline: April 21, 2022

Application Deadline: April 30, 2022

Website: <https://pardeefoundation.org/how-to-apply/>

#### **5. HD Human Biology Project, Huntington's Disease Society of America**

The Human Biology Project was launched in 2013 with the goal of fostering innovative research in collaboration with HD clinics to better understand the biology of Huntington's disease as it occurs in humans. HDSA encourages researchers to consider one of HDSA's 50 Centers of Excellence as a potential collaborator, but applicants may propose to work with any HD clinic around the world.

Eligibility requirements (partial list):

- Preference given to young postdoctoral and clinical investigators (PhD and/or MDs) who are not yet independent
- Innovative ideas from non-scientists will also be accepted and encouraged
- Applications are welcomed and encouraged from individuals from other areas of research and health care (e.g., biostatisticians, physical therapists, etc).
- Mentors: If the applicant is a post-doctoral or clinical research fellow, a mentor must be identified before applying for the HD Human Biology Project. All mentors must have a PhD and/or MD/DO degree and be scientific investigators with primary appointments at academic, public or private research institutions. Collaborations between multiple HD clinics are strongly encouraged.

Citizenship: Unrestricted

Award Amount: \$75,000-\$150,000 paid over 1-2 years

Indirect Costs: None

LOI Deadline: May 6, 2022

MGB Research Management Deadline: June 28, 2022

(Invited) Application Deadline: July 8, 2022

Website: <http://hdsa.org/hd-research/hd-human-biology-project/>

## **6. User-Centric Insulin Pumps, JDRF **NEW!****

JDRF is a longstanding supporter of artificial pancreas (AP) systems, also known as automated insulin delivery (AID) or hybrid closed loop (HCL) systems. Despite demonstrated benefits of AP systems for glucose control, there are significant barriers to widespread adoption, including user burden associated with insulin pump use. JDRF invites letters of intent to develop insulin pumps with improved form factor and other “user-centric” features that improve user experience so as to enable greater adoption of pumps and AP systems.

Today there are multiple AP systems commercially available in the United States and abroad. AP systems, which are comprised of an insulin pump, a continuous glucose monitor (CGM), and a control algorithm, improve HbA1c, increase time-in-range, and reduce time spent in hypoglycemia. AP systems also have the potential to improve quality of life by reducing the burden of disease management; however, for many this benefit is stymied by the on-body burden of wearing an insulin pump, which results in some people with T1D choosing not to take advantage of AP system technology despite the proven clinical benefits. This RFA is intended to solicit projects to develop “user-centric” pumps that impose less physical and psychological burden on people with T1D as well as people with type 2 diabetes who use insulin.

Citizenship: Unrestricted

Award Amount: Up to \$4.5 million over 3 years  
Indirect Costs: 10%  
LOI Deadline: May 10, 2022  
MGB Research Management Deadline: July 1, 2022  
(Invited) Proposal Deadline: July 13, 2022  
Website: <https://grantcenter.jdrf.org/rfa/user-centric-insulin-pumps/>

### **7. Improving Detection of Neurotoxicity in Immunotherapies, Johnson & Johnson (J&J)**

There are new immunotherapy cancer treatments available for hematologic malignancies, such as T-cell based immunotherapies and chimeric antigen receptor T-cell (CAR-T) therapies. However, some patients experience neurotoxicity as a result of treatment. Clinical symptoms or signs can be progressive and may include aphasia, altered level of consciousness, impairment of cognitive skills, motor weakness, seizures, and cerebral edema.

Although sometimes severe, neurotoxicity is primarily reversible and can be detected through specialized patient monitoring and care. Early detection of acute toxicities may enable earlier intervention and ultimately result in improved outcomes for patients. For example, research suggests that analyzing patients' handwriting may aid in identifying neurotoxicity prior to the presentation of other noticeable symptoms.

To inspire early identification of neurotoxicity, Johnson & Johnson Innovation, together with Janssen Global Services, is proud to launch the Improving Detection of Neurotoxicity in Immunotherapies QuickFire Challenge. Visionaries are invited to submit methods and technologies aiming to optimize patient care for immunotherapies within the hematologic malignancy space by enabling early detection of neurotoxic events. Of particular interest are technologies aiming to identify clinical manifestations to predict acute toxicities, including movement and neurocognitive disorders.

Citizenship: Unrestricted

Award Amount: Grant funding up to increments of \$200,000, \$125,000, and \$75,000  
Indirect Costs: Unspecified  
MGB Research Management Deadline: May 4, 2022  
Application Deadline: May 13, 2022  
Website: <https://jlabs.jnjinnovation.com/quickfire-challenges/improving-detection-of-neurotoxicity-in-immunotherapies>

### **8. Maternal-Fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity, Johnson & Johnson (J&J)**

We believe that improving health equity for individuals across the spectrum of humanity is a core responsibility. To help profoundly change the trajectory of health for humanity, we feel we must help address health inequities impacting BIPOC communities. We are committed to crowdsourcing and enabling innovative solutions from diverse innovators that have the

potential to change the course of healthcare in communities that have been historically marginalized.

Improved and accessible diagnostics could allow for early detection of high-risk immune-mediated pregnancies and referral to specialty care, enabling better health outcomes for pregnant individuals of all communities. A study from 2015 found that after implementing neonatal screening for severe combined immunodeficiency (SCID), the prevalence of SCID in Black and Hispanic individuals was higher than previously reported by clinical referrals to transplant centers for definitive treatment, suggesting that disease differences among various racial and ethnic groups could be the result of having inequitable access to screening and specialty care and that increasing universal screenings could be a potential solution.

To that end, Johnson & Johnson Innovation, in collaboration with the Office of the Chief Medical Officer (OCMO) Health of Women team, together with Janssen Research & Development, is proud to launch the Maternal-fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity. US-based innovators are invited to submit data-driven research methodologies, tools, or technologies that aim to better understand the manifestations of immune-mediated diseases of pregnancy impacting historically marginalized communities. Potential solutions should inform or catalyze the crucial next steps needed to develop diagnostics and novel therapies aiming to improve immune-mediated pregnancy outcomes in mothers and children from BIPOC communities.

Citizenship: United States

Award Amount: \$500,000 available

Indirect Costs: Unspecified

MGB Research Management Deadline: May 24, 2022

Application Deadline: June 3, 2022

Website: <https://jllabs.jnjinnovation.com/quickfire-challenges>

### **9. Fellows Award in Premature Mortality, MQ: Transforming Mental Health**

MQ: Transforming Mental Health invites proposals for its fellows award. This supports early-career scientists who are asking challenging questions that will contribute to transformative advances in mental health research as they establish their independence. In the 2022 call the focus of the projects should be on the premature death. Research can be based in the laboratory, clinic or field and may involve theoretical, experimental, social science or medical humanities approaches to the remit.

This MQ Fellows Award will have the theme “Gone too Soon”. People affected by mental illness and mental distress die too soon; their lives are scandalously short. Suicide is one contributing factor. However, a major reason is the close link between physical and mental health causing people with severe mental illness to die of preventable physical causes. Young

adults with severe mental illness are five times more likely to have three or more physical health conditions than their peers.

Projects should be focused on the premature death among people suffering from mental illness and mental distress; primarily due to suicide or comorbidities and charter pathways to genuine impact via, for example, understanding mechanisms or developing effective and scalable solutions.

Eligibility requirements (partial list):

- Have a PhD, DPhil, DClinPsy, MBBS, MD or equivalent
- Have accumulated 3-7 years whole-time-equivalent research experience, equivalent in nature to postdoctoral research
- Be able to show that this award will help to establish independence relative to current position

Citizenship: Unrestricted

Award Amount: £225,000 GBP ( $\approx$  \$294,000) paid over 3 years

Indirect Costs: None

MGB Research Management Deadline: April 20, 2022

Application Deadline: April 29, 2022

Website: <https://www.mqmentalhealth.org/research-programmes/fellows-award/>

### **10. Childhood Eczema Challenge Grant, Pediatric Dermatology Research Alliance (PeDRA)**

This Challenge Grant is intended to stimulate early and mid-career scientists as they seek to build and sustain careers as research investigators and future thought leaders within this critical field of study. Research proposals should address at least one of the following priorities related to pediatric eczema:

- **Eczema Heterogeneity: Novel Insights**  
Projects aimed at advancing understanding of the underlying factors contributing to the diversity of pediatric eczema clinical presentation, treatment response and comorbidities.
- **Innovations in Clinical Practice & Care**  
Studies addressing approaches to facilitate optimal identification and treatment of pediatric eczema and associated comorbidities in all health care settings to enhance patient/caregiver-reported and patient/caregiver-centric outcomes.
- **Understanding & Alleviating Disease Burden**  
Insightful proposals that identify, quantify or aim to reduce aspects of pediatric eczema burden that negatively affect patient or family/caregiver quality of life (including lifestyle, academic, occupational, or economic impacts) based on patient population, treatment approach, etc.
- **Eczema Prevention**



Novel investigations into the potential risk factors and strategies of primary eczema prevention in the pediatric population.

Priority will be given to proposals that focus on clinical or translational research and are broadly applicable. Proposals that include basic research will be accepted, however they should be combined with a significant clinical or translational component. Proposals related to the development or enhancement of mobile apps will not be accepted.

Eligibility requirements (partial list):

- Early and mid-career investigators (Associate Professor level or below and within 15 years of finishing training) are eligible to apply.
- Applicants need not be trained in pediatric dermatology but must hold the degree of MD and/or PhD (or equivalent) and be eligible to apply for grants under the guidelines of their host institution.
- Applications may be submitted by either a single investigator or multiple investigators at multiple institutions.
- Applicants may not hold current R-level funding from NIH (or equivalent) as PI or Co-PI, however recipients of past or current NEA and/or PeDRA grants are eligible to apply.

Citizenship: Unrestricted

Award Amount: \$50,000 for 1 year

Indirect Costs: None

MGB Research Management Deadline: May 20, 2022

Application Deadline: June 1, 2022

Website: <https://pedraresearch.org/2022/01/17/childhood-eczema-challenge-grant-applications-being-accepted/>